Out-licensing: Biotechnology & Blood and forming organs & Phase I

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Open Innovation for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Partneringtools; Reports; Partnering Consulting; Due Diligence; Comparison
Due Diligence: Overview; Top Applications; Online Panel Discussions; Request Consultation
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs; Forums
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing Ltd
is a division of

Up-to-date access to technology licensing opportunities worldwide.

Displaying 1..4 of 4 - per page
Order by

rHu G-CSF More

POL6326, a CXCR4 antagonist, currently in Phase I clinical studies More

Peg GCSF More

In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients . More

Displaying 1..4 of 4 - per page
Order by

Industry sector: Assay systems; Diagnostic test systems; Gene therapy; Human diagnostics; Human therapeutics; Nanotechnology; Other; Research supplies; Stem cells
Therapeutic target: Blood composition; Blood disorders; Blood substitute; Blood Transfusion; Fibrogenesis; Hemorrhagic trauma; Lymphatic disorders; Sepsis; Thrombosis; Whole blood substitute

Industry news: Pharmalicensing provides comprehensive industry coverage.